{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:01:03Z","timestamp":1793898063537,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Moderna"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.vaccine.2018.01.029","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T04:09:02Z","timestamp":1518667742000},"page":"1689-1699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"title":["Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity"],"prefix":"10.1016","volume":"36","author":[{"given":"Shinu","family":"John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Yuzhakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Deterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ciaramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.029_b0005","doi-asserted-by":"crossref","first-page":"e1005355","DOI":"10.1371\/journal.ppat.1005355","article-title":"The march towards a vaccine for congenital CMV: rationale and models","volume":"12","author":"Bialas","year":"2016","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.029_b0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.029_b0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpeds.2007.12.049","article-title":"A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection","volume":"153","author":"Foulon","year":"2008","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.029_b0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00006454-199202000-00007","article-title":"Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality","volume":"11","author":"Boppana","year":"1992","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.029_b0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0042-1748054","article-title":"Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus","volume":"11","author":"Dahle","year":"2000","journal-title":"J Am Acad Audiol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.029_b0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2055-6640(20)30457-X","article-title":"Human cytomegalovirus and transplantation: drug development and regulatory issues","volume":"2","author":"McIntosh","year":"2016","journal-title":"J Virus Erad"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.029_b0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.vaccine.2018.01.029_b0045","series-title":"Vaccines for the 21st century: a tool for decisionmaking","author":"Stratton","year":"2000"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.029_b0050","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/jvi.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2018.01.029_b0055","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0060","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/infdis\/165.2.381","article-title":"Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity","volume":"165","author":"Marshall","year":"1992","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.029_b0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.drudis.2016.03.005","article-title":"Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design","volume":"21","author":"Blanco-Lobo","year":"2016","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.029_b0075","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1084\/jem.168.3.919","article-title":"Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses","volume":"168","author":"Borysiewicz","year":"1988","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.01.029_b0080","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/340637","article-title":"Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals","volume":"185","author":"Kern","year":"2002","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0042-6822(84)90193-4","article-title":"Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus","volume":"135","author":"Britt","year":"1984","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.029_b0090","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1128\/jvi.62.9.3309-3318.1988","article-title":"Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)","volume":"62","author":"Britt","year":"1988","journal-title":"J Virol"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2018.01.029_b0095","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/vir.0.83523-0","article-title":"Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection","volume":"89","author":"Gerna","year":"2008","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jcv.2011.06.018","article-title":"Serum antibody response to the gH\/gL\/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections","volume":"52","author":"Genini","year":"2011","journal-title":"J Clin Virol"},{"issue":"52","key":"10.1016\/j.vaccine.2018.01.029_b0105","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1016\/j.vaccine.2012.10.053","article-title":"Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus","volume":"30","author":"Fu","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2018.01.029_b0110","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.029_b0115","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.029_b0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.01.029_b0125","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.029_b0130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/CVI.00037-07","article-title":"Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins","volume":"14","author":"Reap","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0135","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.029_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","article-title":"Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells","volume":"82","author":"Ryckman","year":"2008","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2018.01.029_b0145","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/bit.25670","article-title":"Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system","volume":"112","author":"Hofmann","year":"2015","journal-title":"Biotechnol Bioeng"},{"issue":"50","key":"10.1016\/j.vaccine.2018.01.029_b0150","doi-asserted-by":"crossref","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"30","key":"10.1016\/j.vaccine.2018.01.029_b0155","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.029_b0160","doi-asserted-by":"crossref","first-page":"e1004524","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog"},{"issue":"362","key":"10.1016\/j.vaccine.2018.01.029_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2015.973859","article-title":"mRNA transcript therapy","volume":"14","author":"Weissman","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.029_b0175","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"7644","key":"10.1016\/j.vaccine.2018.01.029_b0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2018.01.029_b0185","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.029_b0190","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2018.01.029_b0195","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.029_b0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0042-6822(88)90071-2","article-title":"Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage","volume":"167","author":"Spaete","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.01.029_b0205","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/ncomms9176","article-title":"Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody","volume":"6","author":"Chandramouli","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.029_b0210","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.029_b0215","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.029_b0220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.029_b0225","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/CVI.00011-09","article-title":"Biologic and immunologic effects of knockout of human cytomegalovirus pp65 nuclear localization signal","volume":"16","author":"Zaia","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.029_b0230","doi-asserted-by":"crossref","first-page":"e59863","DOI":"10.1371\/journal.pone.0059863","article-title":"Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection","volume":"8","author":"Lilleri","year":"2013","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.vaccine.2018.01.029_b0235","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"Potzsch","year":"2011","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.vaccine.2018.01.029_b0240","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2002-08-2502","article-title":"Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease","volume":"101","author":"Gamadia","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.029_b0245","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3324\/haematol.11912","article-title":"Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection","volume":"93","author":"Lilleri","year":"2008","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.vaccine.2018.01.029_b0250","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1128\/JVI.74.17.8140-8150.2000","article-title":"Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors","volume":"74","author":"Gillespie","year":"2000","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.029_b0255","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.4161\/hv.22447","article-title":"Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice","volume":"8","author":"Shedlock","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2018.01.029_b0260","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1371\/journal.pcbi.0020109","article-title":"High epitope expression levels increase competition between T cells","volume":"2","author":"Scherer","year":"2006","journal-title":"PLoS Comput Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.01.029_b0265","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1084\/jem.192.8.1105","article-title":"T cells compete for access to antigen-bearing antigen-presenting cells","volume":"192","author":"Kedl","year":"2000","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.vaccine.2018.01.029_b0270","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus vaccines: current status and future prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:53Z","timestamp":1759400693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0264410X1830063X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.029","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732705037.793550979","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}